$ILLUM

Prenetics Global's CEO highlighted significant growth prospects for their IM8 platform at a recent conference. The company expects to achieve revenue between $180 million and $200 million, signaling strong demand and expansion. This guidance reiterates confidence in their business model and market demand for genetic testing services. Such growth potential is likely to attract investor interest, enhancing stock performance. Overall, the positive outlook may impact related stocks in the health technology sector.